BIOTRANSPLANT AND METHOD FOR TREATING CHRONIC LOWER EXTREMITY ISCHEMIA CASES

• Main Authors: GOL'DSHTEJN DMITRIJ VADIMOVICH, GORNOSTAEVA SVETLANA NIKOLAEVNA, MAKAROV ANDREJ VITAL'EVICH, LITVINOV SERGEJ SERGEEVICH, RZHANINOVA ALLA ANATOL'EVNA, SHAMENKOV DMITRIJ ALEKSEEVICH, SABURINA IRINA NIKOLAEVNA, BAZHANOV NIKOLAJ ALEKSANDROVICH, FATKHUDINOV TIMUR KHAJSAMUDINOVICH, PULIN ANDREJ ALEKSEEVICH
• Format: Patent
• Language: English; Russian
• Published: 27.10.2006
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

FIELD: medicine. ^ SUBSTANCE: biotransplant has mesenchyma stem cells. Tissues at gestation stages of 5-8 weeks for liver, 18-20 weeks for thymus, 17-20 weeks for bone marrow, 17-19 weeks for subcutaneous fat are used as fetal material. Donor material like bone marrow, subcutaneous fat tissue and thymus is taken from 6 years old children and used in following auto- or allotransplantation operations. Biotransplant for treating the cases of chronic lower extremity ischemia complications contains myoblasts taken from skeletal muscles. Fetal skeletal muscles taken during 1-2 gestation trimester are used as fetal material. Adult people muscle tissue taken as a result of skeletal muscle biopsy is used as donor and autologic material. Biotransplant for treating the cases of ulcero-necrotic complications of chronic lower extremity ischemia contains fibroblast suspension obtained from fetal skin at the 1-2 gestation trimester, adult people skin obtained in plastic surgery operations or biopsy, lyposuction materials. Method involves carrying out femoropopliteal or femorotibial autovenous bypass operation with concurrently introduced cellular transplant. 100-500 mln of mesenchyma stem cells are introduced into common femoral artery in 20 ml of infucol or physiologic saline and 100-500 mln of mesenchyma stem cells are intramuscularly introduced with 5-10 injections in 5 ml of infucol or physiologic saline. Muscle atrophy being occurred, myoblast culture suspension is to be introduced into injured muscles. Ulcero-necrotic complications being observed, a series of injection around the defect is administered using suspension containing mesenchyma stem cells and fibroblasts to 100 mln of cells in 1 ml of infucol or physiologic saline. ^ EFFECT: enhanced effectiveness of treatment. ^ 12 cl